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3 Cutaneous leishmaniasis (CL) is a major health problem in many countries and its current treatment 
4 involves multiple parenteral injections with toxic drugs and requires intensive health services. 
5 Previously, the efficacy of a single subcutaneous injection with a slow-release formulation consisting 
6 of poly(lactide-co-glycolide) (PLGA) microparticles loaded with an antileishmanial 3-nitro-2-
7 hydroxy-4,6-dimethoxychalcone (CH8) was demonstrated in mice model. In the search for more 
8 easily synthesized active chalcone derivatives, and improved microparticle loading, CH8 analogues 
9 were synthesized and tested for antileishmanial activity in vitro and in vivo. The 3-nitro-2’,4’,6’-
10 trimethoxychalcone (NAT22) analogue was chosen for its higher selectivity against intracellular 
11 amastigotes (selectivity index = 1489, as compared with 317 for CH8) and more efficient synthesis 
12 (89% yield, as compared with 18% for CH8). NAT22 was loaded into PLGA / polyvinylpyrrolidone 
13 (PVP) polymeric blend microspheres (NAT22-PLGAk) with average diameter of 1.9 µm. Although 
14 NAT22-PLGAk showed similar activity to free NAT22 in killing intracellular parasites in vitro (IC50 
15 ~ 0.2 µM), in vivo studies in Leishmania amazonensis – infected mice demonstrated the significant 
16 superior efficacy of NAT22-PLGAk to reduce the parasite load. A single intralesional injection with 
17 NAT22-PLGAk was more effective than eight injections with free NAT22. Together, these results 
18 show that NAT22-PLGAk is a promising alternative for single-dose localized treatment of CL.
19
20 Keywords: Leishmania; chemotherapy, drug delivery systems, local treatment, chalcone. 
21






24 Leishmaniasis is a neglected disease caused by intracellular protozoans of the genus Leishmania. 
25 Depending on the parasite species and the patient's immune status, this disease may present a wide 
26 spectrum of clinical manifestations ranging from cutaneous leishmaniasis (CL), the most benign 
27 form, to life-threatening visceral leishmaniasis (VL). Although not fatal, CL is the most common 
28 form of the disease, which is endemic in 87 countries and affects almost 1 million people every year, 
29 according to World Health Organization (WHO) estimates (WHO, 2017). Uncomplicated CL is 
30 characterized by one or more skin ulcers at the sandfly bite site that evolves for weeks to months, 
31 normally leaving a permanent scar. In some individuals the disease may progress to extremely 
32 morbid diffuse or mucosal forms (Aronson and Joya, 2019). Currently available treatments for CL 
33 are toxic and require intensive health services. For example, first-line therapy uses 20-30 daily 
34 intramuscular or intravenous injections with antimonials, pentamidine, or amphotericin B, which 
35 produces severe adverse reactions and poor patients’ compliance. Liposomal formulations of 
36 amphotericin B have appeared as a less toxic alternative treatment, but the high cost and invasive 
37 administration have limited their widespread use (Uliana et al., 2017). An ideal CL treatment should 
38 not only heal the cutaneous lesions, but also prevent the development of the more morbid forms of 
39 disease (Aronson and Joya, 2019). 
40 Chalcones have appeared as a promising new class of antileishmanials (de Mello et al., 2014; Ortalli 
41 et al., 2018). They are characterized by the presence of a 1,3-diphenylprop-2-en-1-one scaffold and 
42 have, in addition to their antileishmanial effects, a broad spectrum of pharmacological activities. 
43 Indeed, chalcones are known to affect bacteria (Kunthalert et al., 2014; Li et al., 2016), fungi (Tiwari 
44 et al., 2010; Łacka et al., 2011) and helminths (De Castro et al., 2015), and to have 
45 immunosuppressive properties (Luo et al., 2012). We have previously demonstrated the activity in 
46 vitro and in vivo of a natural methoxychalcone and its synthetic derivatives against Leishmania 





47 amazonensis (Torres-Santos et al., 1999a; Boeck et al., 2006). Its synthetic analogue 3-nitro-2’-
48 hydro-4’,6’-dimethoxychalcone, named CH8, displayed the highest in vitro selectivity index against 
49 L. amazonensis (S.I. = 318 in relation to murine macrophages). Additionally, intralesional injections 
50 with CH8 were more effective than the reference drug sodium stibogluconate in a murine model of 
51 CL caused by L. amazonensis (Boeck et al., 2006). The oral efficacy and safety of CH8 were also 
52 demonstrated in BALB/c mouse infections with L. amazonensis and L. infantum (Sousa-Batista et 
53 al., 2018a). More recently, the efficacy of a single injection with CH8 was achieved by loading the 
54 drug in biodegradable poly (lactic-co-glycolic acid) (PLGA) microparticles (Sousa-Batista et al., 
55 2018b). The drug encapsulation allows prolonged release in the lesion and, in leishmaniasis, has the 
56 advantage of being taken up by phagocytic macrophages (Sousa-Batista and Rossi-Bergmann, 2018).
57 Although CH8 is a promising drug candidate, its burdensome synthesis and purification is a pitfall in 
58 pharmaceutical development. Aiming to solve this problem, in the present work we proposed to 
59 identify active CH8 analogues with easier purification and better synthesis yield. The ultimate goal 
60 of this study was to choose the best analogue to encapsulate in PLGA microparticles and, thus, to 




65 Chalcone CH8 (3-nitro-2-hydroxy-4,6-dimethoxychalcone) was synthesized by aldol condensation 
66 as previously described (Boeck et al., 2006). All starting materials were commercially obtained 
67 (Merck, Germany). Fifty analogues were produced but only those with acceptable synthesis yield are 
68 described here. The chalcone analogue 1 (NAT 1) was prepared by a condensation reaction in which 
69 the appropriately substituted acetophenone (1 equiv) was added to an aqueous alcoholic solution 
70 (40% v/v EtOH in water) of sodium hydroxide (3% w/v NaOH in water; 3 equiv) with stirring and 





71 with cooling of the reaction mixture in an ice bath during the addition. The mixture was allowed to 
72 warm to room temperature (25 ºC), and the appropriately substituted benzaldehyde (1 equiv) was 
73 added with vigorous stirring until the product precipitation (Kumar et al., 1985). The analogues 
74 NAT22, NAT28, NAT31, and NAT49 were prepared by Claisen-Schmidt condensation (Amslinger 
75 et al., 2012) between aromatic acetophenones (1 equiv) and corresponding aldehydes (1 equiv) in 
76 methanol- Ba(OH)2 (1 equiv) at 50 ºC with magnetic agitation for 12–48 h. The products were 
77 purified by column chromatography or on preparative TLC plates to yield the corresponding 
78 chalcone. For the analogues NAT31 and NAT49, a further step of deprotection was done: to each 
79 chalcone in dry CH2Cl2 was added dropwise a solution of BCl3 in hexane at –78 °C (Amslinger et 
80 al., 2012), after which the solution was stirred for 3 h at 0 °C. All of the synthesized compounds 
81 have been previously described, and their spectral data corresponded to that in the literature. 
82 Individual yields of the compounds were as follows: NAT1 = 61%; NAT22 = 89%; NAT28 = 81%; 
83 NAT31 = 12% and NAT49 = 13%. 
84
85 3.2. PLGAk and NAT22-PLGAk microparticles 
86 Microparticles were prepared by an emulsion and solvent evaporation process. The polymers 
87 Poly(lactide-co-glycolide) 50:50 (PLGA - Purac 504, Purasorb, Corbion, Netherlands) and 
88 polyvinylpyrrolidone (PVP - Kolidon K17, BASF, Germany), at final concentration of 90% and 10% 
89 were dissolved in dichloromethane (DCM – Vetec, Brazil). NAT22 (10%) was dissolved in this 
90 solution and the resulting homogenous mixture injected into an aqueous phase containing Polyvinyl 
91 alcohol (PVA - Sigma-Aldrich, EUA), 3% (w/v). The mixture was emulsified by agitation in an 
92 Ultra-Turrax T25 Basic (Ika, Germany) for 2 min at 13000 rpm on ice. The organic phase 
93 evaporation was performed under reduced pressure using a rotary evaporator (LOGEN Scientific, 
94 Brazil). After solvent full evaporation, the obtained microparticles (NAT22-PLGAk) were washed 





95 with water and centrifuged at 9000 rpm at 4 ºC. Finally, the microparticles were dispersed in 
96 trehalose 5% and cooled to −18 °C for subsequent freeze-drying (FreeZone 1 lyophilizer, Labconco 
97 Corporation, EUA). The freeze-dried microparticles were stored at 4 °C. Empty microparticles 
98 (PLGAk) were prepared following the same procedure, but without added NAT22.  
99 Average particle size and its distribution were measured by a laser light scattering analyzer 
100 (Zetasizer 3000, Malvern Instruments, Malvern). The particles were dispersed in 0.5% (w/w) Tween-
101 20 solution and subsequently submitted to ultrasound for 20 s.
102  The drug present in the microparticles was determined directly by measuring the amount of NAT22 
103 entrapped in the microparticles. Briefly, microparticles were accurately weighed and dissolved in 5 
104 mL acetonitrile (Vetec, Brazil) by bath sonication until complete solubilization was achieved. 
105 Absorbance of appropriately diluted stock solutions was measured at 320 nm (SpectraMax M5), and 
106 the NAT22 concentration was calculated using calibration curves (correlation coefficient > 0.999) 
107 over a concentration range of 10 to 60 mg/L NAT22. All samples were measured in triplicate.
108 The shape and surface of the microparticles was studied using a scanning electron microscope (SEM, 
109 JSM-5600LV, JEOL, Japan) operating at an acceleration voltage of 20 kV under nitrogen 
110 atmosphere. Before SEM analysis, the dry microparticles were coated by sputtering with gold (JFC-
111 1300, JEOL, Japan). 
112
113 3.3. In vitro antileishmanial activity
114 Antileishmanial drug activity was determined against both the promastigote and the intracellular 
115 amastigote forms of L. amazonensis (MHOM/BR/75/Josefa strain). 
116 For antipromastigote studies, 2 × 105 promastigotes/mL of  medium 199 supplemented with 5% heat-
117 inactivated fetal bovine serum (HIFBS - Cutilab, Brazil) were first incubated in triplicate with each 
118 compound (0, 0.1, 1, 10 and 100 µM) to determine the IC50 range, and again with 2- fold dilutions 





119 for a more precise determination. All cultures including controls contained 1% dimethyl sulfoxide 
120 (DMSO – Sigma-Aldrich, EUA). After 72 h at 26 °C, cell viability was measured by the MTS Cell 
121 Proliferation Colorimetric Assay Kit (Promega, EUA) using a plate-reader spectrometer 
122 (SpectraMax M5, Molecular Devices, EUA) at 490 nm. The results were expressed as the drug 
123 concentration that inhibited parasite growth by 50% (IC50, calculated as in 3.6 below). 
124  For anti-amastigote activity, 5 × 105 mouse peritoneal macrophages were plated on glass coverslips 
125 and infected with 5 × 106 promastigotes (1:10) at 34 °C for 4 h, when non-internalized parasites were 
126 washed away with phosphate buffered saline (PBS). After 24 h of incubation in RPMI supplemented 
127 with 5% HIFBS at 37°C, the amastigote-infected macrophages were treated with varying 
128 concentrations of compounds for 48 h. NAT22-PLGAk concentrations were relative to NAT22 
129 content, while PLGAk concentrations were relative to its content in NAT22-PLGAk. Treatment time 
130 in the particle assay was increased to 96 h to allow more time for polymer degradation and drug 
131 release (Sousa-Batista et al., 2018c). Then, coverslips were stained with Giemsa for cell counting 
132 under microscope (400x). Parasite loads in culture were calculated as total numbers of amastigotes / 
133 200 total macrophages. 
134
135 3.4. Macrophages viability evaluation
136 Adherent mouse peritoneal macrophages were cultured in triplicate at 37 °C with two-fold dilutions 
137 of compounds for 48 h (analogue assay) or 96 h (microparticle assay). The release of the cytoplasmic 
138 enzyme lactate dehydrogenase (LDH) into the culture medium was measured using an assay kit 
139 (Doles, Brazil) and a plate-reader spectrometer (SpectraMax M5) at 340 nm, as a cytotoxicity 
140 indicator. Maximum and minimum release values were obtained with cells cultured with 2% Triton 
141 X-100 or medium, respectively, and LDH release was calculated as percent of the positive control. 
142 Equation: % specific release = [(test release - spontaneous release) / (maximal release - spontaneous 





143 release)] x 100. Representative results from three independent experiments were expressed as the 
144 drug cytotoxic concentration for 50% of cell in culture (CC50).
145
146 3.5. In vivo antileishmanial activity and ethical standards.
147 The CL model used was 8-week-old female BALB/c mice weighing about 23 g, as previously 
148 approved by the institutional Animal Care and Use Committee of the Federal University of Rio de 
149 Janeiro (protocol number CAUAP118). To compare the efficacy of CH8 and NAT22 against CL, 
150 five BALB/c mice / group were infected in the ear pinna with 106 promastigotes of green 
151 fluorescence protein GFP- L. amazonensis (Costa et al., 2011) at the stationary phase of growth. 
152 After 7 days of infection, animals were given local s.c. injections with 1.2 mg/kg of NAT22 (3.3 µg 
153 /injection) or 10 µl of the vehicle alone (PBS) twice a week during 4 weeks (Sousa-Batista et al., 
154 2018b). Alternatively, they received a total of 8 injections with NAT22 alone twice a week during 4 
155 weeks. The parasite loads in the individual lesions were expressed as arbitrary fluorescence units 
156 (Demicheli et al., 2004). The fluorescence intensity of contralateral uninfected ears was subtracted 
157 from that of the treated ears. Alternatively, mice were given a single s.c. injection with 3.3 µg of 
158 NAT22 alone or equivalents in NAT22-PLGAk. Controls received the same dose of empty PLGAk, 
159 or 10 µl of PBS alone. On day 32 of infection, animals were anesthetized with isoflurane, sacrificed 
160 by cervical dislocation, the ears removed, grounded and assayed by limiting dilution assay (LDA) for 
161 determination of parasite loads (Lima et al., 1997).  
162  
163 3.6. Statistical analysis
164 Groups were compared using unpaired Student´s t test and considered different when p < 0.05. IC50 
165 and CC50 values were calculated by logarithmic regression analysis from a sigmoidal dose-response 





166 curve. Data was normalized to run from 0% to 100% using a normalized dose-response equation. All 
167 analyses were conducted using GraphPad Prism 5 software. 
168
169 4. RESULTS
170 The need for CH8 analogues with better yields led us to synthesize approximately 50 molecules, 
171 however only the chalcones that could be synthesized more efficiently than CH8 will be shown in 
172 this work. Table 1 contains the synthesis efficiency of 5 analogues as well as their antileishmanial 
173 activity. The overall yield for each was superior to that obtained with CH8 (18%), with the highest 
174 yield (89%) being obtained for NAT22. The inhibitory activity of the analogues was tested against 
175 the amastigote and promastigote forms of L. amazonensis. CH8 displayed the highest 
176 antipromastigote activity (IC50 = 0.7 µM), followed by NAT22 (IC50 = 1.9 µM). All the compounds 
177 displayed potent inhibitory effects against the amastigote form of L. amazonensis, with NAT22 
178 displaying the highest activity (IC50 = 0.1 µM). None of the analogues had detectable cytotoxicity 
179 against murine macrophages, as indicated by the low specific release of LDH enzyme (CC50 > 100 
180 µM). As previously noted, the nitro group is important for optimal antiparasitic effect (activity / 
181 selectivity), as demonstrated by the superior performance of CH8 vs. NAT49 and of NAT22 vs. 
182 NAT28.
183 Since NAT22 was the most active compound and its synthesis was simpler and more efficient than 
184 that of CH8 (85% and 18%, respectively), this compound was chosen for evaluation of its efficacy in 
185 a murine model of CL. Intralesional treatment with NAT22 demonstrated significant efficacy in 
186 reducing parasite load when compared to untreated controls. At the same treatment regimen (8 doses 
187 of 3.3 µg each), although NAT22 was slightly more effective than CH8 in preventing parasite 
188 growth, the difference was not statistically significant (p>0.05) (Fig 1). 





189 With the goal of improving its local efficacy in CL, NAT22 was loaded into biodegradable 
190 polymeric microparticles. To this end, microparticles composed of a mixture of PLGA and PVP 
191 polymers were prepared by a solvent evaporation technique, yielding particles with 9.5% 
192 encapsulated NAT22 (NAT22-PLGAk). Empty microparticles were also prepared. The loaded and 
193 empty microparticles showed similar topography, with a round smooth surface (Fig 2B) and 
194 diameters of 1.90 ± 0.01 µm (dispersion = 2.30 ± 0.07 µm) and 2.60 ± 0.13 µm (dispersion = 3.57 ± 
195 2.10 µm) respectively, as measured by light laser scanner (not shown). Figure 2A shows by SEM the 
196 crystalline structures of unencapsulated NAT22. Drug crystals were not seen outside the 
197 microparticles allowing a durable effect, suggesting a high drug internalization (Fig 2B). 
198 When NAT22 was tested for inhibition of intracellular amastigotes, entrapment into microparticles 
199 did not significantly increase drug activity (p>0.05), as shown in Table 2. None of the NAT22 
200 presentations were cytotoxic to macrophages as measured by release of the cytoplasmic enzyme 
201 LDH (Table 2). Finally, we tested the efficacy of single-dose subcutaneous treatment with NAT22-
202 PLGAk in CL (Fig. 3). The safety of PLGA s.c. injection was previously demonstrated in mice using 
203 PLGA- CH8 formulation (Sousa-Batista et al., 2018b). Mice receiving a single intralesional injection 
204 with NAT22-PLGAk had, 25 days later, only 11% of the number of parasites present in animals 
205 receiving the PBS vehicle alone (100%). The resulting efficacy was higher than that obtained with a 
206 single or even eight doses of unencapsulated NAT22.
207
208 5. DISCUSSION
209 Previously, we have described the promising efficacy of the nitrochalcone CH8 for the intralesional 
210 treatment of CL caused by L. amazonensis (Boeck et al., 2006). However, the low synthesis yields 
211 together with difficult drug purification showed to be a bottleneck in the process scale up due to 





212 interconversion of a percentage of resulting CH8 with a flavanone. Five CH8 analogues were then 
213 synthesized with fewer purification steps and higher yields. 
214 Previous studies have shown that modifications in the positions of substituents in the structure of 
215 chalcones can improve their antileishmanial effects (Nielsen et al., 1998; Kayser and Kiderlen, 2001; 
216 Boeck et al., 2006). We produced five easily synthesized CH8 analogues bearing modifications in 
217 both aromatic rings and observed that the nitro group was important for their ability to inhibit L. 
218 amazonensis growth in vitro. The nitro group has also been demonstrated to be important in anti-
219 trypanosome activity (Patterson and Wyllie, 2014). The nitrochalcone NAT22 was selected for 
220 further in vivo studies due to its high synthesis yield and better antileishmanial activity. 
221 A single intralesional injection with NAT22 resulted in 40% reduction in local parasite load 
222 measured 3 weeks later. That effect is similar to observed with CH8 (37%), although in vitro NAT22 
223 demonstrated an anti-amastigote activity greater than CH8 (0.1 and 1.4 μM, respectively). The 
224 relative low water solubility and large crystals shown in Fig.2 may have provided a slow dissolving 
225 depot in the injection site, providing a longer lasting effect. Although an effective and short 
226 treatment for CL is highly desirable, the problem with the crystalline nature is needle clogging and 
227 difficult dose reproducibility.
228 To circumvent NAT22’s poor water solubility and chemical stability, we attempted to entrap it in 
229 PLGA particles, as demonstrated previously with CH8 (Sousa-Batista et al., 2018b). PLGA, a 
230 copolymer of lactic acid and glycolic acid, has been shown to be safe and effective for use in 
231 sustained-release drug delivery systems, and has also been clinically approved for other uses, such as 
232 absorbable suture threads, orthopedic scaffolds, and treatment of localized tumors (Ortega-Oller et 
233 al., 2015; Wan and Yang, 2015). In order to increase NAT22 loading efficiency, reduce the initial 
234 burst release and to improve delivery characteristics, similar to that previously observed for CH8, 
235 PLGA was blended with the polymer polyvinylpyrrolidone (PVP) (Sousa-Batista et al., 2018c). This 





236 PVP effect is due to its higher solubility in organic polymer solution that result in extensive diffusion 
237 of PVP molecules into the dispersed droplets of polymer solution during microparticle preparation 
238 and its high capacity to interact with drug by hydrogens bonds (Meeus et al., 2013, 2015). Thus, the 
239 PLGA/PVP polymer blend (PLGAk) was used to improve NAT22-PLGA interaction, and the 
240 process was adjusted to provide particles with an average diameter of 1.9 µm, a size large enough to 
241 allow phagocytosis by macrophages and yet prevent absorption into blood circulation. Such particle 
242 size provides a potential advantage compared to both injected intralesional antimonials that require 
243 repeated injections (Oliveira-Neto et al., 1997) and smaller poly-lactide nanoparticles (Torres-Santos 
244 et al., 1999b) or larger PLGA microparticles (Sousa-Batista et al., 2018b) that have been used to 
245 carry subcutaneous chalcone implants. Additionally, the NAT22-PLGAk formulation is a single dose 
246 treatment, meeting the DNDi Target Product Profile for CL that recommends the use of treatments 
247 with few injections, local effect and low cost. It is worth noting that despite the technology adding 
248 cost, a single dose treatment will have positive impact in reduced hospital and mobility costs.
249 We found NAT22-PLGAk inhibited parasite growth inside macrophages in vitro, but this effect was 
250 not superior to unencapsulated NAT22, probably due to the fact that the time employed in the in 
251 vitro assay was not sufficient to achieve maximum chalcone release from the microparticles, as seen 
252 previously with CH8-PLGA (Sousa-Batista et al., 2018b). It is conceivable that PVP has further 
253 slowed the intracellular release, and therefore less NAT22 was available to produce its effect on the 
254 parasite during the 96-hour assay. Recently, we reported that amphotericin B release from PLGA 
255 microparticles is much faster in the subcutaneous ear tissue (30 days) than in saline solution in vitro 
256 (200 days), possibly because of presence of enzymatic hydrolysis in the tissue (Sousa-Batista et al., 
257 2019). Whether or not NAT22 release from PLGAk microparticles follows the same kinetics remains 
258 to be determined.  In addition to showing good anti-amastigote activity, NAT22-PLGAk did not 
259 induce cytotoxic effects against mammalian macrophages, supporting its safety and promise as a 





260 therapeutic tool in vivo. It appears that the anti-amastigote effect of NAT22-PLGAk is due to 
261 intracellular drug targeting rather than to macrophage activation of NO production, as this function 
262 was not affected in treated macrophages (data not shown). This is in accordance with the results 
263 obtained previously with free or encapsulated CH8 (Sousa-Batista et al., 2018b) and with the well-
264 known antioxidant (Sivakumar et al., 2011) and anti-inflammatory (Herencia et al., 1999) properties 
265 of chalcones. However, other potential microbicidal mechanisms of NAT22-PLGAk should not be 
266 discarded. Since, although to a much lesser extent than NAT22-PLGAk, empty PLGAk alone 
267 displayed some inhibitory effect on the intracellular parasites (IC50 > 10 µM), suggestive of a 
268 macrophage stimulatory effect of PLGA microparticles (Luzardo-Alvarez et al., 2005). 
269 In this work, the use of NAT22 plus the polymer blend (PLGA/PVP) in the microparticle 
270 composition allowed an increased drug content (9.5% w/w), in contrast to the previous CH8 plus 
271 PLGA which maximally incorporated 7.8% of drug (Sousa-Batista et al., 2018b). More importantly, 
272 the easier and more efficient NAT22 synthesis yield (89%) as compared with CH8 (18%) will further 
273 reduce production costs. Because the currently available treatments for localized CL are invasive and 
274 produce systemic side effects, NAT22-PLGAk appears promising for single-dose local use. The 
275 mouse ear model of CL used here appears translatable to the human infection as the drug is 
276 discharged in the subcutaneous tissue not on the skin surface where differential skin permeability 
277 would be more critical. Future studies on local drug kinetics, evaluation of efficacy over extended 
278 time periods, and use of other relevant parasite species like L. braziliensis and L. tropica will add 
279 further insight to this new mode of CL therapy.
280
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409 Table 1. Synthesized chalcone analogues and their in vitro activity and safety
410









CH8 OH OCH3 NO2 18 0.7 ± 0.2 1.4 ± 0.1
>100
(444*)
NAT1 H H H 61 24.0 ± 0.1 1.7 ± 0.2 >100(191*)
NAT22 OCH3 OCH3 NO2 89 1.9 ± 0.1 0.1 ± 0.2
>100
(149*)
NAT28 OCH3 OCH3 OCH3 81 6.7 ± 0.1 1.0 ± 0.1
>100
(165*)
NAT31 OH OCH3 OCH3 12 4.5 ± 0.1 0.7 ± 0.1
>100
(216*)
NAT49 OH OCH3 OH 13 3.0 ± 0.1 1.2 ± 0.1
>100
(206*)
411 Maximum and minimum release optical densities were = 1.824 ± 0.003 and 1.014 ± 0.014. Means  
412 SD (n = 3). * CC50 values as extrapolated from curve fitting. 
413
414





416 Table 2: Anti-amastigote activity and cytotoxicity of free and microparticulated NAT22. 




NAT22 0.2  0.1 >100 (179*)
NAT22-PLGAk 0.3  0.1 >100 (154*)
PLGAk >100 (130*) >100 (318*)
417 Maximum (2 % Triton 100-X) and minimum LDH release values were = 1.824 ± 0.003 and 1.014 ± 
418 0.014, respectively. Means  SD (n = 3). * CC50 values as extrapolated from curve fitting. No 
419 concentrations higher than 100 µM were used due to dense particle deposits over cell monolayers. 







423 Figure 1. Effect of free chalcones in L. amazonensis-infected mice. BALB/c mice were infected 
424 with L. amazonensis-GFP in the ear. From day 7 of infection they were treated twice a week with 
425 CH8 or NAT22 at a total dose of 1.2 mg/kg (3.3 µg/dose/10 µl) or with 10 µl of vehicle alone (PBS) 
426 for 4 weeks. Parasite loads were measured on day 32 of infection and expressed as specific 
427 fluorescence units (FU). Means ± SD (n = 5), *** p< 0.05 in relation to PBS. 
428
429 Figure 2. Scanning electron microscopy of: A) Large crystal structures of free NAT22, and B) 
430 Microparticle-entrapped NAT22 (NAT22-PLGAk).
431
432 Figure 3. Efficacy of NAT22-PLGAk in L. amazonensis-infected mice. BALB/c mice were 
433 infected in the ear with L. amazonensis. On day 7 of infection they were given a single (1X) or eight 
434 (8X within 4 weeks), intralesional injections with a total dose of 1.2 mg/kg of NAT22, NAT22-
435 PLGAk, or PLGAk. Parasite loads were measured in the ears on day 32 of infection. Means ± SD (n 
436 = 5). ** p<0.01 in relation of PBS group, # p<0.05.





Figure 1. Effect of free chalcones in L. amazonensis-infected mice. BALB/c mice were infected with L. 
amazonensis-GFP in the ear. From day 7 of infection they were treated twice a week with CH8 or NAT22 at a 
total dose of 1.2 mg/kg (3.3 µg/dose/10 µl) or with 10 µl of vehicle alone (PBS) for 4 weeks. Parasite loads 
were measured on day 32 of infection and expressed as specific fluorescence units (FU). Means ± SD (n = 
5), *** p< 0.05 in relation to PBS. 
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Figure 2. Scanning electron microscopy of: A) Large crystal structures of free NAT22, and B) Microparticle-
entrapped NAT22 (NAT22-PLGAk). 
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Figure 3. Efficacy of NAT22-PLGAk in L. amazonensis-infected mice. BALB/c mice were infected in the ear 
with L. amazonensis. On day 7 of infection they were given a single (1X) or eight (8X within 4 weeks), 
intralesional injections with a total dose of 1.2 mg/kg of NAT22, NAT22-PLGAk, or PLGAk. Parasite loads 
were measured in the ears on day 32 of infection. Means ± SD (n = 5). ** p<0.01 in relation of PBS group, 
# p<0.05. 
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We thank the referees for their time helpful comments which helped us to substantially 
improved our manuscript.
We have carefully considered all comments and answered to them point by point, 
indicating the changes made, as below (in blue):
----------------------------------------------------------------------------------------------------------
Referee: 1
Comments to the Author:
The results of this new approach are promising and providing excellent prospects for 
future research. This research brings a perspective for cutaneous leishmaniasis treatment 
since a single dose of chalcone analogue was effective. Comments and suggestions were 
done in a PDF file.
AUTHORS RESPONSE: We appreciate your relevant comments and suggestions. 
Accordingly, all changes were made, and marked in blue font in the reviewed text.
 
Referee: 2
Comments to the Author: 
In this manuscript Sousa-Batista et al. describe new chalcone analogues for the treatment 
of cutaneous leishmaniasis. A particular difficulty with a previously reported chalcone, 
CH8, was the challenging synthetic route. A new compound presented here, NAT22, is 
much more straightforward to synthesize, and when formulated as a slow release 
microparticle, shows encouraging in vivo activity in a mouse model of CL after a single 
injection. Overall, this manuscript makes an interesting contribution to the development 
of new therapeutics for a highly neglected disease and may trigger further development 
of this approach. The manuscript is of interest to a wide audience of people working on 
leishmaniasis and drug delivery.






I struggle with the reported cell-assay potency values in the manuscript. My 
understanding from the methods is that dose response curves were determined using only 
4 concentrations using a very wide 10-fold dilution scheme (concentrations tested: 0.1, 1, 
10 & 100µM). Using such a scheme it is not possible to determine accurate IC50 values. 
The authors also do not explain how the potencies were determined (e.g. line 101, which 
equation was used, was normalisation applied, what constraints were in place (top and 
bottom fixed?)?).
AUTHORS RESPONSE: Thank you for drawing attention to our mistake. Actually, 10-
fold dilution curves were always used to determine the IC50 range, but subsequent 2-fold 
dilution curves were used to calculate the IC50. Accordingly, that was corrected in lines 
116-117. 
As to data normalization, the information was provided in line 164.
On line 196 the authors state that “entrapment into microparticles increased its IC50 from 
0.2 μM (NAT22 alone) to 0.3 μM (NAT22-PLGAk)”, it is not possible to differentiate 
between these two potencies with the dose response method used, it is also not appropriate 
to return an IC50 of 0.1µM (for NAT22, table 1) when this was the lowest concentration 
tested – the recommendation for accurate IC50s is that there are at least two 
concentrations with 0% effect and two with 100% effect 
(https://onlinelibrary.wiley.com/doi/full/10.1002/pst.426). In my opinion it is impossible 
to determine potencies with 100nM precision using the 4-point dose response curves 
used. I recommend that the authors remove all IC50s, and instead report the lowest actual 
concentration at which >50% (or another threshold) inhibition was seen. Also, in table 1, 
extrapolated values are shown for the CC50, and these are used to calculate the selectivity 
index. I cannot see how these extrapolated values can be anywhere near accurate as the 
only concentration with some cytotoxicity has to be 100µM (as CC50 >100µM). I would 
prefer to see this data also represented as the concentration at which >50% inhibition was 
seen, which means it can probably still be presented as >100. There is no value in a 
selectivity index when accurate IC50s have not been determined so it should be removed 
(just state that the compounds appear not to have any cytotoxic effects at the 
concentrations tested).






 Accordingly, the sentence in lines 196-197 now reads: ‘…entrapment into 
microparticles did not significantly increase drug activity (p>0.05), as shown in 
Table 2.’
 As for promastigotes, curves using 2-fold dilutions that plateaued with the lowest 
and highest concentrations were used for amastigotes. 
 As to CC50 extrapolated values, the curve slopes never went below 70% at 100 
uM - the maximum drug concentration possible. This is explained in the legend 
to Table 2, lines 414-415. 
 As suggested, the selectivity index values were removed both from the main text 
and Tables 1 and 2.
In the discussion it is worth including the need to test against other strains, in particular 
L. tropica, which can be more difficult to treat. 
AUTHORS RESPONSE: We added ‘…and use of other relevant parasite species like L. 
braziliensis and L. tropica will add further insight to this new mode of CL therapy’. (lines 
274-275).
In general it would be useful to discuss the Target Product Profile for cutaneous 
leishmaniasis (https://www.dndi.org/diseases-projects/leishmaniasis/tpp-cl/) and how the 
microparticle approach fits with the ideal or acceptable profile. 
AUTHORS RESPONSE: Thank you for raising this point. The following text was 
introduced in lines 242-245: ‘Additionally, the NAT22-PLGAk formulation is a single 
dose treatment, meeting the DNDi Target Product Profile for CL that recommends the 
use of treatments with few injections, local effect and low cost. It is worth noting that 
despite the technology adding cost, a single dose treatment will have positive impact in 
reduced hospital and mobility costs.’ 
I would also encourage the authors to discuss briefly how translatable the mouse ear 
model is. Are there other models that bear more relevance towards the human condition 
in which this approach should be tested in the future?
AUTHORS RESPONSE: The CL model of mouse ear infection has been widely accepted 





for drug and vaccine tests mainly because of the reproducible measurements of ear 
thickness as compared with other sites, e.g. dorsum area or footpad thickness, and also 
because the ears are out of reach of licking by the mouse.  Since ours is a subcutaneous, 
not topical treatment where differential skin permeability would be critical, the results 
comparing free vs encapsulated drug reported here may be suitable for proof of concept 
purposes. 
In order not to make the Discussion too long, the following was introduced in Lines 271-
273: ‘The mouse ear model of CL used here appears translatable to the human infection 
as the drug is discharged in the subcutaneous tissue not on the skin surface where 
differential skin permeability would be more critical.’
Minor comments:
Line 106: Why different time for compounds +/- microparticles, why not treat for the 
same amount of time?
AUTHORS RESPONSE: We reported previously that 96 h is a more appropriate time to 
evaluate the action of microparticles than 48 h, as it allows more time for polymer 
degradation (Sousa-Batista et al., 2018c) . The text has been modified to make this 
information clearer (lines 127-129): ‘Treatment time in the particle assay was increased 
to 96 h to allow more time for polymer degradation and drug release (Sousa-Batista et 
al., 2018c).’ 
Line 151: Please specify how treatment was applied: topically, injection,…
AUTHORS RESPONSE: Thanks for noting that. Accordingly, we added to Line 150: ‘… 
local  s.c. injections’. 
Line 246: This paragraph discusses encapsulated NAT22, and states that due to its slow 
release there may not have been a full effect in the 48h assay. However, in the methods 
section it states that assays with microparticles were carried out for 96h. Can the authors 
please clarify if it is 48h or 96h?
AUTHORS RESPONSE: Line 251 now reads: “during the 96-hour assay”.  
Please check text for minor typos: line 4: require should be requires, line 34: affect should 
be affects, line 35: according to the WHO estimates should be according to WHO 






AUTHORS RESPONSE: Thanks, the typos have been revised. 
Referee: 3
Comments to the Author:
This is a very interesting paper which addresses the treatment of a very neglected tropical 
disease, cutaneous leishmaniasis. 
I recommend that the paper is accepted after minor amendments as follows:
1. The manuscript needs careful proof-reading as there are occasional grammatical errors.
AUTHORS RESPONSE: Thanks, the manuscript has been revised. 
2. The authors need to add detail on how many infected macrophages were counted per 
sample. It would also be useful to see data on the mean number of parasites per infected 
macrophage, IC50 curves and confidence intervals.
AUTHORS RESPONSE: The number of macrophages counted per sample (200 total 
macrophages) has been added to Line 130. We have not recorded the % of infected 
macrophages because what matters here is the reduction in the numbers of parasites in 
culture, translatable to parasite loads in the lesions.  Statistics is now detailed in Lines 
164-165.
 
3. The discussion needs to be expanded regarding the microparticles. Is there any 
published data on how long these would likely persist at the site of injection and the rate 
at which drug would disperse? 
AUTHORS RESPONSE: Yes, accordingly we have added the following sentence (Lines 
251-255): ‘Recently, we reported that amphotericin B release from PLGA microparticles 
is much faster in the ear subcutaneous tissue (30 days) than in saline solution in vitro 
(200 days), possibly because of presence of enzymatic hydrolysis in the tissue (Sousa-
Batista et al., 2019). Whether or not NAT22 release from PLGAk microparticles follows 
the same kinetics remains to be determined.’
What are the immunosuppressive effects, and would this potentially be an advantage for 
the host or parasite? 





AUTHORS RESPONSE: PLGA is more likely to be an immunostimulant rather than an 
immunosuppressive agent. 
Were any side effects seen in the treated mice?
AUTHORS RESPONSE: The safety of PLGA formulations for mice was tested in 
previous studies of our group, with no evidence of toxicity. The text has been modified 
to show this information.
Lines 199-200: ‘The safety of PLGA s.c. injection was previously demonstrated in mice 
using PLGA- CH8 formulation (Sousa-Batista et al., 2018b).’ 
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